Navigation Links
Aderans Research Treats One-Hundredth Subject in Clinical Study
Date:2/28/2010

Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial’s 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment.

Atlanta, GA (PRWEB) February 28, 2010 -- Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial’s 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment.

“The breadth of this phase of our trial is tremendous,” said Kurt Stenn, MD, Vice President and Chief Scientific Officer. “We have significantly more participants than our Phase 1 study. The improved quantity of our study group allows us to assess our cell-products and accelerate our efforts to truly understand the impact of cell regeneration on pattern hair loss.”

Phase 2 of the study has thus far been conducted in eight cities: Atlanta, Boston, Chicago, New York, Paramus, Raleigh, Houston, and Washington DC. The study will ultimately comprise at least 16 U.S. metropolitan areas, with numerous new cities expected to be added in the coming months.

The second phase of the trial is testing a variety of treatment regimens designed to realize a unique autologous cell engineering solution to hair regeneration. During the treatment, a small section of hair-bearing tissue is removed, cells are extracted and cultivated in a controlled laboratory setting, and then reintroduced to the scalp, where they are expected to elicit new hair growth.

“This is leading edge research in our industry,” said Vern Liebmann, Vice President, Operations. “We’ve been able to conduct this study largely due to the generous financial backing of Aderans Co. LTD of Japan, and we’re collectively very excited to see the results beginning later this year.”

Phase 1 of the clinical study was conducted exclusively in the UK. More than 30% of participants showed a viable response to ARI’s cellular regeneration techniques.

About Aderans Research

Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Company, Ltd, the world’s largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration.

More information on ARI’s study outcomes will be released as studies unfold. To see ARI’s latest clinical updates, please visit http://aderansresearch.com/ari_clinicalupdates.html

Additional information on ARI can be found at www.aderansresearch.com.

Learn more about Aderans Co., Ltd. At http://www.aderans.co.jp/e/company/

###

Read the full story at http://www.prweb.com/releases/hair/regeneration/prweb3661844.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Aderans Research BIO International Press Release
2. Aderans Research Launches Second Phase of Hair Loss Study
3. Veterans Affairs Researchers Induce a New Transmissible Prion Disease
4. Hypnosis can help control pain among women with metastatic breast cancer, UB Researcher finds
5. New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers
6. Greenway Medical Technologies Donates Electronic Health Record, Clinical Research and Revenue Cycle Solutions to Northern Kentucky University
7. Multiple sclerosis, Italian researchers discover a possible onset mechanism for the disease
8. Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Commitment to Pulmonary Fibrosis Research
9. HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say
10. New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery
11. $250,000 Grant Awarded for Groundbreaking Ligament and Tendon Repair Research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Aderans Research Treats One-Hundredth Subject in Clinical Study
(Date:4/29/2016)... ... April 29, 2016 , ... A new ... with severe congenital diaphragmatic hernia have better survival rates if surgery is performed ... (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs into ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... won the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan ... the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... ... and engineer of patented products, announces the Gyrociser, an exercise invention which aids ... worth $2 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about ... of skin cancer deaths. More than 10,000 people are expected to die of melanoma this ... it is the one of the most commonly diagnosed cancers in young women. A recent ...
(Date:4/29/2016)... ... , ... New York City based oral and maxillofacial surgeon Dr. Majid Jamali is ... treat obstructive sleep apnea. Dr. Jamali is proud to offer this permanent solution to patients ... or both jaw bones. This surgery is performed to correct the alignment of the jaw. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
(Date:4/27/2016)... , April 27, 2016 ... Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor ... announced its sales for the first quarter ended March ... and the execution of its commercial strategy. ...
Breaking Medicine Technology: